Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1052837/000110465905053933/a05-18032_110q.htm
March 2006
February 2006
December 2005
December 2005
December 2005
November 2005
October 2005
September 2005
August 2005
July 2005
Exhibit 99.1
|
|
|
Contact: |
Greg Mann |
|
Director |
|
Corporate Communications & Investor Relations |
|
(510) 284-6566 |
FREMONT, Calif. - October 25, 2005 - Abgenix, Inc. (NASDAQ: ABGX) today announced financial results for the third quarter ended September 30, 2005. The company reported a net loss of $36.8 million, or $0.41 per share, for the third quarter of 2005, compared to $42.4 million, or $0.48 per share, for the same period in 2004.
Net cash used in operating activities in the third quarter of 2005 was $21.8 million, compared to $36.5 million in the third quarter of 2004. During the quarter, the company repurchased approximately $13.8 million of its outstanding convertible notes due in 2007, and ended the third quarter of 2005 with $343.6 million in cash, cash equivalents and marketable securities.
We continue to execute on our goals for 2005, including progress with our partner, Amgen, towards the initiation of our regulatory filing to the FDA for panitumumab before year-end 2005, said Bill Ringo, president and chief executive officer of Abgenix. Our third quarter performance reflects expense reductions realized from our recently announced restructuring and facility consolidation, efforts to expand our product portfolio, and investment in the development and potential commercialization of panitumumab.
Revenues for the third quarter of 2005 were $4.7 million compared to $3.1 million for the same period in 2004. Revenues for the third quarter of 2005 consisted primarily of contract revenues from technology licensing agreements and included licensing revenues and an IND-related milestone from our partner Agensys. For the third quarter of 2004, revenues included a milestone payment from Amgen for advancement of denosumab (AMG-162), a XenoMouse®-derived antibody, into pivotal clinical trials for bone loss. The companys contract revenues generally vary from period to period based on the progress of research and development efforts by the companys collaborators and licensees.
-more-
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1052837/000110465905053933/a05-18032_110q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Abgenix Inc.
Abgenix Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2005 10-K Annual Report includes:
CIK: 1052837
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-05-053933
Submitted to the SEC: Wed Nov 09 2005 1:34:48 PM EST
Accepted by the SEC: Wed Nov 09 2005
Period: Friday, September 30, 2005
Industry: Biological Products No Disgnostic Substances